![Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program](https://mma.prnewswire.com/media/446231/Genprex_Logo.jpg?p=twitter)
Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program
![WIRB-Copernicus Group snaps up a pair of clinical analytics companies for undisclosed price | Fierce Biotech WIRB-Copernicus Group snaps up a pair of clinical analytics companies for undisclosed price | Fierce Biotech](https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1533047174/s37-ucb-pr.jpg/s37-ucb-pr.jpg?VersionId=1RR0IbwGXIYne_g9KOltLXuqsbvrBMTV)
WIRB-Copernicus Group snaps up a pair of clinical analytics companies for undisclosed price | Fierce Biotech
![COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker, - ppt download COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker, - ppt download](https://images.slideplayer.com/33/10135875/slides/slide_3.jpg)
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker, - ppt download
WIRB-Copernicus Group and the Prostate Cancer Clinical Trials Consortium Announce New Partnership to Improve Efficiency of Oncology Research Reviews
![A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS - Journal of Cardiac Failure A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS - Journal of Cardiac Failure](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5876209e-e845-49c0-8fbe-9eb52439a47f/gr1_lrg.gif)
A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS - Journal of Cardiac Failure
![Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study | Semantic Scholar Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/09fa1d63f94675acbdb15cd4a5b525828a8d857c/3-Figure2-1.png)
Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study | Semantic Scholar
![COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker, - ppt download COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker, - ppt download](https://images.slideplayer.com/33/10135875/slides/slide_4.jpg)
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker, - ppt download
![Mitchell Psotka on Twitter: "Clinical trial steering committees and sponsors do not aim principally to define disease but to enroll a population that will have sufficient numbers of events to be able Mitchell Psotka on Twitter: "Clinical trial steering committees and sponsors do not aim principally to define disease but to enroll a population that will have sufficient numbers of events to be able](https://pbs.twimg.com/media/E0znplLWEAIkwXX.jpg)